依达拉奉右莰醇联合重复经颅磁刺激治疗脑梗死患者运动障碍的效果  

Effect of edaravone and dexborneol combined with repetitive transcranial magnetic stimulation on dyskinesia in patients with cerebral infarction

作　　者：赖丽琼 王琦威 曾阳阳 彭焱 刘媛 游雄 LAI Liqiong;WANG Qiwei;ZENG Yangyang;PENG Yan;LIU yuan;YOU Xiong(Hunan Rehabilitation Hospital,Changsha 410004,China)

机构地区：[1]湖南省康复医院,湖南长沙410004

出　　处：《中国实用神经疾病杂志》2025年第4期477-481,共5页Chinese Journal of Practical Nervous Diseases

基　　金：2022年湖南省残联康复课题(编号:2022XK0302)。

摘　　要：目的探讨依达拉奉右莰醇联合重复经颅磁刺激治疗脑梗死患者运动障碍的效果。方法纳入湖南省康复医院2022-04—2023-10收治的100例脑梗死患者,随机分为观察组和对照组,各50例,2组均给予基础药物、康复训练及依达拉奉右莰醇治疗,然后予以对照组患者假刺激,予以观察组患者重复经颅磁刺激。比较2组治疗前及治疗后2周、4周、8周简化Fugl-Meyer运动功能评估量表(FMA)、Holden步行功能分级法(FAC)、Berg平衡量表(BBS)、改良Barthel指数量表(MBI)评分,观察2组患者不良反应情况。结果2组治疗后2周、4周、8周FMA、FAC、BBS、MBI评分均较治疗前高,观察组治疗后2周、4周、8周FMA评分[分别为(53.76±10.35)分比(48.62±9.45)分,(58.97±12.46)分比(52.15±10.18)分,(72.48±13.47)分比(64.56±11.36)分]、FAC评分[分别为(1.32±0.28)分比(1.15±0.24)分,(2.68±0.54)分比(1.98±0.42)分,(3.72±0.78)分比(2.59±0.52)分]、BBS评分[分别为(42.64±7.86)分比(38.27±7.43)分,(46.37±5.45)分比(43.25±6.16)分,(51.18±3.21)分比(48.36±4.24)分]、MBI评分[分别为(56.85±10.18)分比(51.21±9.34)分,(63.67±12.48)分比(57.34±11.26)分,(72.55±14.32)分比(64.35±12.69)分]均较对照组升高(P<0.05)。观察组不良反应发生率与对照组相比无统计学差异(10.00%比6.00%,P>0.05)。结论依达拉奉右莰醇联合重复经颅磁刺激治疗脑梗死,可显著促进患者运动功能恢复,提高步行、平衡及日常生活活动能力,具有较好的安全性。Objective To investigate the effect of edaravone and dexborneol combined with repetitive transcranial magnetic stimulation on dyskinesia in patients with cerebral infarction.Methods One hundred patients with cerebral infarction in the Hunan Rehabilitation Hospital from April 2022 to October 2023 were selected and randomly divided into observation group and control group,with 50 cases in each group.Both groups were given basic drugs,rehabilitation training and edaravone and dexborneol treatment,while the control group was given sham stimulation and the observation group was given repetitive transcranial magnetic stimulation.The simplified Fugl-Meyer assessment scale(FMA),Holden functional ambulation category scale(FAC),Berg balance scale(BBS)and modified Barthel index scale(MBI)scores were compared between the two groups before treatment and 2,4 and 8 weeks after treatment.The adverse reactions of the two groups were observed.Results The scores of FMA,FAC,BBS and MBI in the two groups were higher than those before treatment,and the scores of FMA(53.76±10.35 vs 48.62±9.45,58.97±12.46 vs 52.15±10.18,72.48±13.47 vs 64.56±11.36,respectively),FAC(1.32±0.28 vs 1.15±0.24,2.68±0.54 vs 1.98±0.42,3.72±0.78 vs 2.59±0.52,respectively),BBS(42.64±7.86 vs 38.27±7.43,46.37±5.45 vs 43.25±6.16,51.18±3.21 vs 48.36±4.24,respectively)and MBI(56.85±10.18 vs 51.21±9.34,63.67±12.48 vs 57.34±11.26,72.55±14.32 vs 64.35±12.69,respectively)in the observation group were higher than those in the control group(P<0.05).Compared with the control group,there was no significant difference in the incidence of adverse reactions in the observation group(10.00%vs 6.00%,P>0.05).Conclusion Edaravone and dexborneol combined with repetitive transcranial magnetic stimulation in the treatment of patients with cerebral infarction can significantly promote the recovery of motor function,improve the ability of walking,balance and activities of daily living,and has better safety.

关 键 词：脑梗死 运动障碍 依达拉奉右莰醇 重复经颅磁刺激 步行能力 平衡能力 

分 类 号：R743.33[医药卫生—神经病学与精神病学]